Attachment

coronavirus-disease-covid-2019-5060427_1920

Cells research

Original size is 1920 × 1280 pixels

Vaxine is an Australian-based biotechnology company that over the last 20 years has developed an extensive portfolio of vaccines and immunotherapies, including vaccines against Covid-19, influenza, hepatitis B, and Japanese encephalitis plus immunotherapies against allergy and cancer. Underlying all these successful vaccines is Vaxine’s powerful vaccine adjuvant technology plus its capabilities in applying artificial intelligence to rapid drug design.

About
People
Projects

Publications
News
Contact

News

Phase 2 trial results April 22, 2022
TGA grants Provisional Determination to Vaxine for its COVID-19 Recombinant Protein Vaccine April 1, 2022
Efficacy of COVID-19 vaccines (Video) September 21, 2021